Neuro-Hitech Pharmaceuticals, Inc. Appoints David Barrett (MACC ’99)
Chief Financial Officer; Barrett Adds M&A, Tax and Audit, and Start-Up Experience to Neuro-Hitech

Last Update: 10:22 AM ET Apr 6, 2006

NEW YORK, Apr 06, 2006 (BUSINESS WIRE) -- Neuro-Hitech Pharmaceuticals, Inc. (NHPI), a
drug development company engaged in the development and commercialization of Huperzine A
(HupA) and its analogues for Alzheimer's and other degenerative neurological disorders, today
announced that it has appointed David Barrett as its Chief Financial Officer.

Barrett comes to Neuro-Hitech from Overture Financial Services, LLC, (OFS) where he was CFO.
OFS specializes in the construction and management of investment platforms for financial
intermediaries, Previously, Mr. Barrett was CFO at Overture Asset Managers, LLC where he was
responsible for managing the finances, business, acquisition and operation strategy for the firm
and its affiliates.

Before working with Overture, he worked with Deloitte & Touche for four years, focusing his
talents on Mergers and Acquisitions after serving in the firm's Tax and Audit Practice. Barrett was
the Senior Consultant on the broker-dealer audit for two major investment-banking clients. He
also served on Deloitte's committee that dealt with Sections 302 and 404 of Sarbanes-Oxley.
Barrett is a Certified Public Accountant in the states of New York and Connecticut. He earned a
Masters in Accounting at the University of Florida in 1999, where he also received his Bachelor's
of Science in Finance & Accounting in 1999.

Reuben Seltzer, President and CEO of Neuro-Hitech, said, "David Barrett brings to our company
the complete set of financial and accounting skills and experience that we need to succeed. His
familiarity with tax and audit issues is critical to any small-cap company. His experience will
further allow us to make wise decisions about expanding upon our portfolio of compounds
through mergers or acquisitions. Additionally, his understanding of Sarbanes-Oxley, which he
gained through daily experience at Deloitte, is of considerable value in these times, especially to
a growing company. His management abilities, as demonstrated in his work on numerous audits
as Deloitte, will help us build a motivated and energized staff across our organization. Finally, his
experience at Overture as CFO gives him a familiarity with the day-to-day functions he will be
called upon to execute as our CFO. Those functions will include regularly meeting with investors
and analysts, and we expect he will rapidly become one of the public faces of Neuro-Hitech."

Barrett commented, "I am looking forward to a long and productive relationship with Reuben and
the rest of the Neuro-Hitech Management Team. The development of new medical therapies is
both a scientific and financial challenge, and I am confident that my training and talents will help
in commercializing Huperzine A and our other development initiatives. In addition, I am committed
to making sure that investors and analysts get a constant and clear picture of exactly where
things stand both scientifically and financially. As the scientific side of Neuro-Hitech develops
Huperzine A and as it adds new compounds and therapies to its portfolio, it will be my
responsibility to ensure that the Company remains a solid investment story, and I am very excited
by the Company's potential."

About Neuro-Hitech Pharmaceuticals, Inc.

Neuro-Hitech Pharmaceuticals, Inc. is a drug development company engaged in the development
and commercialization of Huperzine A (HupA) and its analogues for a variety of degenerative
neurological disorders.